 |
Urinary incontinence is defined as a loss of bladder control that results in involuntary urine leaking. Control over the urinary sphincter is impaired or lost with this illness, causing a person to urinate even when they do not want to. This is a very common and frequently humiliating issue for people. When urinating, the muscles around the urethra relax and allow urine to travel out of the body; however, in urinary incontinence, the muscles around the urethra do not operate as they should, resulting in urine leakage. There are several types of incontinence, including stress (pressure on the bladder), urge (strong need to discharge pee), and overflow (chronic urinary retention). Urinary incontinence severity varies according to health problems such as urinary tract infection (UTI), constipation, and age group, since urinary incontinence is more common in the elderly population.
The worldwide urinary incontinence treatment medicines market is predicted to be worth $4,180.6 million in 2020, with a CAGR of 3.8 percent over the forecast period (2020-2027).
For example, Astellas Pharma Inc. got FDA clearance in 2018 for its supplementary new drug application (sNDA) for the use of mirabegron in conjunction with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urine incontinence.
For example, in 2016, Cipla Limited = got an Abbreviated New Drug Application (ANDA) from the U. S. Food and Drug Administration (FDA) for Darifenacin extended-release tablets for the treatment of overactive bladder with symptoms of urge urine incontinence, urgency, and frequency.
The primary limiting factors for the urine incontinence treatment medicines market growth include unfavorable side effects such as constipation, dry skin, dry eyes, and upset stomach, poor efficacy of existing medications and difficulties in illness identification, and ignorance regarding urinary incontinence diseases.
The worldwide urinary incontinence treatment medicines market is predicted to be worth $4,180.6 million in 2020, with a CAGR of 3.8 percent over the forecast period (2020-2027).
For example, Astellas Pharma Inc. got FDA clearance in 2018 for its supplementary new drug application (sNDA) for the use of mirabegron in conjunction with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urine incontinence.
For example, in 2016, Cipla Limited = got an Abbreviated New Drug Application (ANDA) from the U. S. Food and Drug Administration (FDA) for Darifenacin extended-release tablets for the treatment of overactive bladder with symptoms of urge urine incontinence, urgency, and frequency.
The primary limiting factors for the urine incontinence treatment medicines market growth include unfavorable side effects such as constipation, dry skin, dry eyes, and upset stomach, poor efficacy of existing medications and difficulties in illness identification, and ignorance regarding urinary incontinence diseases.